Vismodegib

Overview

No Reviews

Credits

1.00

Post Assessment Questions

5

Expiration Date

31 Dec 2025

Last Reviewed

1 Jan 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Initially approved in 2012, vismodegib is the first FDA-approved pharmacologic agent that targets the Hedgehog signaling pathway (sonic hedgehog, SHH), a pathway involved in many basal cell carcinomas. Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC), accounting for over one-half of all NMSC diagnoses. BCC affects over 3.3 million a year in the United States. Approximately 40% of patients diagnosed with BCC will develop another BCC within five years of the initial diagnosis. Management is primarily with surgical intervention, except in some cases where topical therapy is utilized. Not all patients are suitable candidates for surgery or topical treatment due to locally advanced or metastatic basal cell carcinoma; this is where vismodegib has a place in therapy. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring, of vismodegib so providers can direct patient therapy in cancer treatment where it is indicated as part of the interprofessional team.

UAN: JA4008195-9999-23-1966-H04-P

Target Audience

This activity has been designed to meet the educational needs of pharmacists.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the types of cancer for which vismodegib is indicated.
  • Outline the adverse event profile of vismodegib.
  • Describe the place vismodegib has in the treatment of basal cell carcinoma.
  • Review how interprofessional team strategies can improve care coordination and communication to properly use vismodegib to improve patient outcomes for indicated cancers.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. 

COMMERCIAL SUPPORT: This activity has received NO commercial support.

Continuing Education Accreditation Information


Credit provided by Continuing Education, Inc, and StatPearls, LLC.

In support of improving patient care, this activity has been jointly planned and implemented by Continuing Education, Inc./University at Sea® and StatPearls, LLC. Continuing Education, Inc, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is designated for 1.00 contact hours for pharmacists.

FL Board of Pharmacy Tripartite, approval #20-608156.

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content in the activity.
  4. Choose the best answer to each activity test question. To receive credit, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment.
  6. Obtain a certificate.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Disclaimer

Faculty may discuss investigational products or off-label uses of products regulated by the US Food and Drug Administration. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.

  • StatPearlsand and Continuing Education, Inc, reserve the right to cancel any course due to unforeseen circumstances. StatPearls and Continuing Education, Inc, will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Medium or Media Used:

  • Computer Requirements: Internet Access
  • E-mail Address

Equal Opportunity

  • StatPearls and Continuing Education are Equal Opportunity/Affirmative Action/Equal Access Institutions. 

 

Media Usage Rights

The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity.  All copyrights are reserved.

    Unlimited Pharmacist CE

    Stay up to date on the latest medical knowledge with 3450 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 3968.5 hours of CE.

    Single Activity

    Take this single activity

    $19 1 activity

    6 Month Unlimited Pharmacist CE

    Access to all the Unlimited Pharmacist CE activities in all specialties.

    $59 per half year per user

    1 Year Unlimited Pharmacist CE

    Access to all the Unlimited Pharmacist CE activities in all specialties.

    $99 per 1 year per user